3,300 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,300 shares of the biopharmaceutical company's stock, valued at approximately $2,351,000.

Other large investors have also recently bought and sold shares of the company. Pamalican Asset Management Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $4,915,000. Intact Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $356,000. Rhenman & Partners Asset Management AB lifted its position in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after purchasing an additional 4,457 shares in the last quarter. Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners grew its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after acquiring an additional 1,272 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. Finally, Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $5.32 during trading on Monday, reaching $589.00. The company's stock had a trading volume of 156,233 shares, compared to its average volume of 787,476. The firm has a market cap of $63.59 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a 50 day moving average of $599.96 and a 200-day moving average of $681.90.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.